Differences in Botulinum Toxin Dosing Between Patients With Adductor Spasmodic Dysphonia and Essential Voice Tremor

被引:11
|
作者
Orbelo, Diana M. [1 ,2 ]
Duffy, Joseph R. [2 ]
Borst, Becky J. Hughes [1 ]
Ekbom, Dale [1 ]
Maragos, Nicolas E. [1 ]
机构
[1] Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Neurol, Div Speech Pathol, Rochester, MN 55901 USA
关键词
Spasmodic dysphonia; Botulinum toxin; Tremor; Dystonia; Dystonic tremor; Essential voice tremor; SPASTIC DYSPHONIA; VOCAL TREMOR; LARYNGEAL DYSTONIA; RISK-FACTORS; EXPERIENCE; MANAGEMENT;
D O I
10.1016/j.jvoice.2013.05.008
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
Objectives. To explore possible dose differences in average botulinum toxin (BTX) given to patients with adductor spasmodic dysphonia (ADSD) compared with patients with essential voice tremor (EVT). Methods. A retrospective study compared the average BTX dose injected in equal doses to the thyroarytenoid (TA) muscles of 51 patients with ADSD with 52 patients with EVT. Results. Those with ADSD received significantly higher total doses (6.80 +/- 2.79 units) compared with those with EVT (5.02 +/- 1.65 units). Dose at time of first injection, age at time of first injection, gender, year of first injection, and average time between injections were included in multivariate analysis but did not interact with total average dose findings. Conclusions. Patients with ADSD may need relatively higher doses of BTX injections to bilateral TA muscles compared with patients with EVT.
引用
收藏
页码:123 / 127
页数:5
相关论文
共 50 条
  • [41] Spasmodic dysphonia follow-up with videolaryngoscopy and voice spectrography during treatment with botulinum toxin
    Marcello Esposito
    R. Dubbioso
    P. Apisa
    R. Allocca
    L. Santoro
    U. Cesari
    Neurological Sciences, 2015, 36 : 1679 - 1682
  • [42] Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section
    Sulica, L
    Blitzer, A
    Brin, MF
    Stewart, CF
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2003, 112 (06) : 499 - 505
  • [43] Effects of botulinum toxin on pathophysiology in spasmodic dysphonia
    Bielamowicz, S
    Ludlow, CL
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2000, 109 (02) : 194 - 203
  • [44] Efficacy of botulinum toxin in treatment of spasmodic dysphonia
    Petrovic, Igor
    Svetel, Marina
    Vasic, Milan
    Kostic, Vladimir
    TOXICON, 2008, 51 : 34 - 34
  • [45] Voice Disorders in the Workplace: Productivity in Spasmodic Dysphonia and the Impact of Botulinum Toxin
    Meyer, Tanya K.
    Hu, Amanda
    Hillel, Allen D.
    LARYNGOSCOPE, 2013, 123 : S1 - S14
  • [46] Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan
    Hyodo, Masamitsu
    Asano, Kento
    Nagao, Asuka
    Hirose, Kahori
    Nakahira, Maya
    Yanagida, Saori
    Nishizawa, Noriko
    TOXINS, 2021, 13 (12)
  • [47] Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients: A Systematic Review
    van Esch, Babette F.
    Wegner, Inge
    Stegeman, Inge
    Grolman, Wilko
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2017, 156 (02) : 238 - 254
  • [48] Outcomes assessment following treatment of spasmodic dysphonia with botulinum toxin
    Courey, MS
    Garrett, CG
    Billante, CR
    Stone, RE
    Portell, MD
    Smith, TL
    Netterville, JL
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2000, 109 (09) : 819 - 822
  • [49] Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update
    Hyodo, Masamitsu
    Hirose, Kahori
    Nagao, Asuka
    Nakahira, Maya
    Kobayashi, Taisuke
    TOXINS, 2022, 14 (07)
  • [50] Botulinum toxin injections for essential voice tremor
    Hertegård, S
    Granqvist, S
    Lindestad, PÅ
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2000, 109 (02) : 204 - 209